Funded Grants

1. Treatment of Glioma, PAR-02-139, NINDS Cooperative Program in Translational Research Direct Costs: $492,608 (Principal Investigator for UMN U01 portion), September, 2006-August, 2011; funded

2. Stem Cells for CNS Therapies in MPS Type 1, NIH/NINDS submitted grant, Direct Costs: $1,250,000 (Co-Investigator, application submitted)

3. Research Grant to the CNS Gene Therapy Consortium for Gene therapy of Spine Disorders; Direct Costs $150,000 (Principal Investigator, October, 2005-May, 2007)

4. Development of Conference on Gene and Cellular Therapy for Spine Disorders. Synthes Spine, Inc., Direct Costs: $85,000 (Principal Investigator, November, 2003-October, 2004)

5. Development of Gene and Cellular Therapy for Spine Disorders. Synthes Spine, Inc., Direct Costs: $65,000 (Principal Investigator, October, 2002-October, 2003)

6. Aspartoacylase Gene Transfer in brain/Canavan Disease, RO1 NS42120-1, NIH/NINDS Pilot Clinical Grant, Total Costs: $583,258 (principal clinical investigator, 2001-2003, extension to 2007)

7. Towards Gene Therapy of Parkinson’s Disease. NIH-RO1 NS 39144 Direct Costs: $756,000 (co-investigator, 1999-2002)

8. Development of gene therapy approaches to Parkinson’s Disease.  Progen, Inc.   Direct Costs:  $80,000  (Principal Investigator, 2000)

9. Gene Therapy of Canavan Disease. Strawbridge Research Fund, Direct Costs: $150,000 (Principal Investigator, 1999-2000)